Cepheid Revenue and Competitors

Location

$117.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Cepheid's estimated annual revenue is currently $750M per year.(i)
  • Cepheid's estimated revenue per employee is $127,378
  • Cepheid's total funding is $117.9M.

Employee Data

  • Cepheid has 5888 Employees.(i)
  • Cepheid grew their employee count by -2% last year.

Cepheid's People

NameTitleEmail/Phone
1
Sr. Product Owner - Digital SolutionsReveal Email/Phone
2
Chairman & CEOReveal Email/Phone
3
Chief IP CounselReveal Email/Phone
4
Chief Product Security Officer/Director SoftwareReveal Email/Phone
5
Executive Assistant to VP, Strategic DevelopmentReveal Email/Phone
6
VP, Manufacturing FinanceReveal Email/Phone
7
VP Quality (OUS)Reveal Email/Phone
8
VP, Software Engineering, R&DReveal Email/Phone
9
VP, Global Training & DevelopmentReveal Email/Phone
10
VP, Strategy and Business DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.5M3827%N/AN/A
#2
$158.4M79114%$2.3MN/A
#3
$42310M1699955%N/A$226.6B
#4
$84.2M4570%$2.6MN/A
#5
$38M24547%N/AN/A
Add Company

What Is Cepheid?

Cepheid develops, manufactures, and markets fully-integrated systems that perform genetic analysis, including DNA and RNA analysis, for the clinical genetic assessment, biothreat, and life sciences markets. Our systems enable rapid, sophisticated genetic testing of organisms by automating otherwise complex manual laboratory procedures. Genetic testing involves a number of complicated steps, including sample preparation, amplification and detection. Based on state-of-the-art microfluidic and microelectronic technologies, our easy-to-use systems integrate these steps and analyze complex biological samples in our proprietary test cartridges. We are focusing our efforts on those applications where rapid genetic testing is particularly important, such as the infectious disease, cancer and biothreat testing markets. Our SmartCycler® and GeneXpert® systems can perform a broad range of genetic tests that include identifying infectious organisms and evaluating at-risk populations for the early detection of disease. Physicians can also determine the stage of a disease, such as cancer, and assess what therapy might be most effective. We have also adapted our systems to enable the rapid detection and identification of organisms that may serve as biothreat agents.

keywords:Biotechnology

$117.9M

Total Funding

5888

Number of Employees

$750M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cepheid News

2022-04-20 - Tuberculosis Diagnostics and Treatment Market Size, Outlook ...

Cepheid Inc, Becton Dickinson, Hain LifeSciences, Abbott Laboratories, Alere, Roche AG, Hologic Corporation, bioMerieux, Sanofi, QIAGEN, Akonni Biosystems,...

2022-04-19 - Cepheid Developing Xpert Test to Distinguish Between ...

LISBON, Portugal – Cepheid is developing an assay for its flagship GeneXpert platform to differentiate bacterial from viral infections in...

2022-04-19 - Clinical Microbiology Market Size, Outlook And Forecast ...

BioMerieux, Cepheid, Danaher, Bruker, Becton Dickinson, Hologic, Roche Diagnostics, Alere. This comprehensive Clinical Microbiology Market...

2021-07-29 - Cepheid : Receives CE-IVD Clearance for Two Next-Generation Xpert® HIV-1 Tests

SUNNYVALE, Calif., July 29, 2021 /PRNewswire/ -- Today Cepheid announced that it has received CE-IVD clearance for Xpert® HIV-1 Viral Load XC and Xpert® HIV-1 Qual XC, next-generation extended-coverage (XC) tests for HIV testing. Xpert® HIV-1 Viral Load XC adds a second target for HIV-1 detecti ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3130M8082N/AN/A
#2
$1290M82018%$481M
#3
$5490M9425100%N/A
#4
$1970.9M97092%N/A
#5
$3560M98032%$19.2M